Introduction: Anemia is a condition in which the number of red blood cells (RBCs) or their oxygen-carrying capacity is insufficient to meet physiologic needs of the body and is characterized by a constellation of symptoms. Ayurveda compares the symptoms of anemia with that of the disease Pandu. Punarnavadi Mandura, Dadimadi Ghrta, Navayasa Churna, and Dhatri Lauha are few among the multitudes of medicines that are currently prevalent in use for the management of Pandu. However, the safety of these drugs were not evaluated until now through clinical drug trials.
INTRODUCTION
Anemia is a condition characterized by reduced circulating hemoglobin in the body and it often acts as a major disease or as a secondary condition associated with many other diseases. Iron deficiency is the major contributor to anemia globally. World Health Organization (WHO) estimates that prevalence of anemia is 14% in developed countries, 51% in developing countries, and 65 to 75% in India. 1 The National Family Health Survey 2(4) and 3(5), Indian Council of Medical Research estimates reveal the prevalence of anamia to be over 70% in preschool children, over 70% in pregnant women and adolescent girls. 2 Iron deficiency is defined as a condition in which there is depletion of mobilizable iron stores in the body and associated with signs of insufficient supply of iron to tissues. The more severe stages of iron deficiency are associated with anemia. 3 When iron-deficient erythropoiesis occurs, hemoglobin concentrations are reduced to below optimal levels. When individual hemoglobin levels are below two standard deviations (-2SD) of the distribution mean for hemoglobin in an otherwise normal population of the same gender and age who are living at the same altitude, IDA is considered to be present. 3 Although the etiology of IDA is multifaceted, it generally results when the iron demands by the body are not met by iron absorption, regardless of the reason. Individuals with IDA have inadequate intake, impaired absorption or transport, physiologic losses associated with chronological or reproductive age, or chronic blood loss secondary to disease. 4 The modern management of IDA is done through oral and parenteral iron therapy which is associated with many adverse effects, such as nausea, abdominal discomfort, diarrhea, and constipation in oral use and hypersensitive reactions, hemolysis, hypotension, circulatory collapse, vomiting, and muscle pain in parental therapy. Hence, it is the need of the current medical world to explore complementary and alternative systems of medicine to come up with alternative options which are safe and effective at the same time. Ayurveda has explained in detail about the disease Pandu roga in almost all major classics, which is symptomatically similar to IDA and has described the symptoms, types, pathogenesis, its therapeutic and other interventions in detail. Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta are few among the multitudes of formulations in Ayurveda that are presently in use. This set of studies was done to analyze the safety of Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta in patients with IDA.
Drug Profile
Ayurveda has considered Pandu as a symptom as well as disease, and the drugs mentioned in this context have rakta poshana (nourishing blood), deepana (potentiating digestive activity), doshaanulomana (normalizing the doshic mechanism), srotosodhana (clearing the microchannels of circulation), and dhatu preenana (nourishing the body tissues) properties. Drugs are chosen as per the etiology and hence, the legion of drugs mentioned in this context has multifarious actions. Dhatri Lauha 5 is a formulation mentioned in Bhaisajya Ratnavali. Punarnavadi Mandura, 6 Navayasa Churna, 7 and Dadimadi Ghrta 8 are said by Charaka in the context of Pandu roga itself (Table 1) .
OBJECTIVE
Critical analysis and presentation of clinical safety and efficacy outcomes of classical Ayurvedic formulations, viz., Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta in IDA, were generated through multicenter open label studies at different CCRAS centers.
MATERIALS AND METHODS
The formulations fulfilling the physicochemical standards and quality parameters, and prepared as per standard operating procedures, were procured from good manufacturing practice-certified companies for all the studies. every 2 weeks to record the onset of any adverse reaction during the intervention. The data thus generated were analyzed to evaluate the safety and efficacy of these drugs in patients with IDA.
Statistical Analysis
Laboratory parameters at the beginning and at the end of the trial period were compared using paired t-test. A p-value of <0.05 was considered significant. All statistical analyses were performed using Statistical Package for Social Sciences, version 15.0.
OBSERVATION

Dhatri Lauha
Among the total 400 patients who completed the trial, majority were females and maximum of the patients belonged to the age group of 21 to 40 years, i.e., 205 patients. About 73.5% were literate and 58.25% hailed from lower socioeconomic stratum. Maximum numbers of patients were housewives, closely followed by students. Among the cardinal symptoms of anemia, weakness was the major symptom seen (99.25%), closely followed by fatigue (98%) and palpitation (60%) during the baseline, and Dhatri Lauha provided significant improvement in all these qualitative parameters. After the trial period, clinical improvement was significantly seen in 79.25% of cases. The therapy also provided statistically significant changes in hematological parameters, such as Hb%, serum iron, serum ferritin, and mean corpuscular hemoglobin concentration (MCHC). Serum bilirubin, serum glutamic pyruvic transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT), serum alkaline phosphatase, total protein, serum albumin, serum globulin, blood urea, and serum creatinine were within normal limits during the entire period. No significant AEs or ADEs were observed during the study.
Punarnavadi Mandura and Dadimadi Ghrta
Among the 90 patients who were selected for the study, 91.1% were females and 51.1% were housewives. About 81.1% of patients were above poverty line and 61.1% were vegetarians. A total of 61.1% of patients belonged to Vata-Pittaja prakrti. The major symptoms noted in the patients were weakness (98.9%), fatigue (98.9%), dizziness (60%), irritability (52.2%), and pallor (56.7%). After the trial period, significant changes were obtained in these parameters and statistically significant change was observed in hematological parameters, such as mean cell hemoglobin concentration (p < 0.001), serum ferritin, and serum iron (p < 0.001). The levels of blood urea, serum uric acid, serum creatinine, SGOT, SGPT, total protein, serum albumin, serum globulin, conjugated bilirubin, unconjugated bilirubin, and serum alkaline phosphatase remained within the specified limits during the trial period. The patients were closely observed during the trial period and no adverse reactions or AEs were identifiable as pertaining to drug interaction.
Navayasa Churna
Among the total 150 patients enrolled in the study, maximum number of patients (26.0%) were found to be in the age group of 32 to 38 years followed by 22.7% in the age group of 39 to 45 years, and 96% of the patients were females. The majority of subjects were observed to be vegetarian (74.0%). Prevalence of anemia was found to be more in Vata-Pittaja prakrti. The major symptoms observed were weakness (79.8%), fatigue (71.3%), pallor (66.1%), shortness of breath (58.8%), and irritability (56.9%). Statistically significant improvement was observed in all these qualitative parameters. The drugs produced significant change in hemoglobin percentage and serum ferritin levels with p-value <0.001. No adverse reactions were noticed during the trial period. Serum bilirubin, SGPT, SGOT, serum alkaline phosphatase, total protein, albumin, globulin, blood urea, and serum creatinine were within normal limits during the entire period. The p-value of all these biochemical parameters was greater than 0.05 and hence, deemed statistically insignificant. The data, regarding demographic profile, efficacy, and safety, obtained from the three studies are given in Tables 3, 4 and Graphs 1 to 4.
DISCUSSION
Anemia is one among the most common nutritional deficiency disorders in the world. The causes for anemia include nutritional deficiencies, external or internal blood loss and increased destruction of RBCs, ineffective or decreased production of RBC, abnormal hemoglobin synthesis, bone marrow suppression by toxins, chemicals, or radiation, infection, bone marrow replacement by malignant cells, etc. 13 Iron deficiency anemia develops when body stores of iron drop too low to support normal RBC production. Inadequate dietary iron, impaired iron absorption, bleeding, or loss of body iron in the urine may be the cause. 14 Modern treatment of IDA consists of correcting the underlying etiology and replenishing of iron stores in the body. The aim of iron therapy is to obtain maximal absorption with a minimum of side effects. To evaluate the effectiveness of oral iron preparations, it is thus necessary to know both their absorbability and their side-effects. On perusing these studies, it is observed that majority of IDA patients are women in the reproductive age group and it can be assumed that it is because of the uncompensated iron depletion in them owing to monthly menstruation, pregnancies, and lactation. The prakrti of these patients were observed to be Vata-Pittaja predominantly and this might be attributed to the fact that dhatu saara attrition owing to vata and pitta are more common in this prakrti. Common symptoms manifested were dizziness, palpitation, weakness, fatigue, and pallor which can be ascribed to the deficient circulation and hypoxia secondary to anemia. The symptoms of anemia point to the functional depletion of rasa and rakta dhatu and these medicines are expected to correct the agnimandya at dhatu level and clear the srotas to enhance the absorption and also stimulate erythropoiesis. In these studies, significant changes were noticed in the aforementioned qualitative parameters and the quantitative parameters, such as serum iron, serum ferritin, serum total iron binding capacity, and hemoglobin. This study was to assess the safety profile of these drugs by analyzing the liver function and kidney function before and after the trial. Drug compliance and development of adverse effects if any were scrutinized. In-depth observations revealed that there there was no significant change in the parameters: Blood urea, serum uric acid, serum creatinine, total protein, serum globulin, serum albumin, SGOT, SGPT, and bilirubin levels in the body, from the baseline, as assessed by statistical evaluation which showed p-value of >0.05, which is statistically insignificant. Hence, it can be concluded that these iron-containing drugs enhance the bioavailability of iron in the body for erythropoiesis without adversely affecting the body in any way. The patients were closely monitored and no ADR/AE could be identified due to drug interaction during the trial period in the case of all four formulations and hence, Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta can be considered to be clinically safe and effective in IDA. 
